Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

Erdem Tüzün; Matthew N. Meriggioli; Julie Rowin; Huan Yang; Premkumar Christadoss

doi:10.1016/j.jaut.2005.01.013

Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

Erdem Tüzün, Matthew N. Meriggioli, Julie Rowin, Huan Yang, Premkumar Christadoss

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.

Original language	English (US)
Pages (from-to)	261-268
Number of pages	8
Journal	Journal of Autoimmunity
Volume	24
Issue number	3
DOIs	https://doi.org/10.1016/j.jaut.2005.01.013
State	Published - May 2005
Externally published	Yes

Keywords

Autoimmunity
Etanercept
Interferon-γ
Interleukin-6
Myasthenia gravis

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaut.2005.01.013

Cite this

@article{8760bae07f674d11b88da64c40262e71,

title = "Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment",

abstract = "Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.",

keywords = "Autoimmunity, Etanercept, Interferon-γ, Interleukin-6, Myasthenia gravis",

author = "Erdem T{\"u}z{\"u}n and Meriggioli, {Matthew N.} and Julie Rowin and Huan Yang and Premkumar Christadoss",

year = "2005",

month = may,

doi = "10.1016/j.jaut.2005.01.013",

language = "English (US)",

volume = "24",

pages = "261--268",

journal = "Journal of Autoimmunity",

issn = "0896-8411",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

AU - Tüzün, Erdem

AU - Meriggioli, Matthew N.

AU - Rowin, Julie

AU - Yang, Huan

AU - Christadoss, Premkumar

PY - 2005/5

Y1 - 2005/5

N2 - Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.

AB - Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.

KW - Autoimmunity

KW - Etanercept

KW - Interferon-γ

KW - Interleukin-6

KW - Myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=17444370887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444370887&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2005.01.013

DO - 10.1016/j.jaut.2005.01.013

M3 - Article

C2 - 15848049

AN - SCOPUS:17444370887

SN - 0896-8411

VL - 24

SP - 261

EP - 268

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

IS - 3

ER -

Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this